MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

Search

Xencor Inc

Fermé

SecteurSoins de santé

8.4 1.69

Résumé

Variation du prix de l'action

24h

Actuel

Min

8.23

Max

8.4

Chiffres clés

By Trading Economics

Revenu

5.5M

-49M

Ventes

-37M

33M

Marge bénéficiaire

-148.576

Employés

250

EBITDA

-21M

-37M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+219.36% upside

Dividendes

By Dow Jones

Prochains Résultats

1 août 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-432M

579M

Ouverture précédente

6.71

Clôture précédente

8.4

Sentiment de l'Actualité

By Acuity

50%

50%

115 / 375 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Strong Bearish Evidence

Xencor Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

5 juil. 2025, 04:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

4 juil. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

4 juil. 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

4 juil. 2025, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

4 juil. 2025, 20:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

4 juil. 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

4 juil. 2025, 16:20 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

4 juil. 2025, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

4 juil. 2025, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

4 juil. 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

4 juil. 2025, 15:57 UTC

Market Talk

Base Metal Prices Fall in Thin, Risk-off Trading -- Market Talk

4 juil. 2025, 15:49 UTC

Market Talk

Gold Futures Set to End Week Flat After Mixed Jobs Report -- Market Talk

4 juil. 2025, 15:49 UTC

Acquisitions, Fusions, Rachats

Credit Agricole: Deal Will Have a Negative Impact of Approximately 30 Basis Points on the Fully-Loaded CET1 Ratio

4 juil. 2025, 15:49 UTC

Acquisitions, Fusions, Rachats

Credit Agricole: Transaction Is Consistent With Targets in Terms of Return of Investment, Return on Tangible Equity

4 juil. 2025, 15:49 UTC

Acquisitions, Fusions, Rachats

Credit Agricole Received All Required Authorizations

4 juil. 2025, 15:48 UTC

Acquisitions, Fusions, Rachats

Credit Agricole: CACEIS and Santander Are Maintaining Their Long-Term Partnership

4 juil. 2025, 15:47 UTC

Acquisitions, Fusions, Rachats

Credit Agricole: Agreement Was Announced on Dec. 19

4 juil. 2025, 15:47 UTC

Acquisitions, Fusions, Rachats

Credit Agricole Now Controls 100% of the Share Capital of CACEIS

4 juil. 2025, 15:46 UTC

Acquisitions, Fusions, Rachats

Credit Agricole Completes Acquisition of Santander's 30.5% Stake in CACEIS

4 juil. 2025, 14:30 UTC

Acquisitions, Fusions, Rachats

Rocky Shore Closes Hemlo Area Claims Sale to Barrick Mining Unit for C$975,000 Cash

4 juil. 2025, 13:53 UTC

Market Talk

Polish Zloty Faces Hit From Prospect of Further Rate Cuts -- Market Talk

4 juil. 2025, 13:41 UTC

Market Talk

Japanese Yen Could Receive Boost From Increased Rate-Hike Bets -- Market Talk

4 juil. 2025, 13:41 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

4 juil. 2025, 13:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

4 juil. 2025, 12:37 UTC

Market Talk

Fund Manager Roundup: U.S. Treasurys in Focus Amid Rising Debt

4 juil. 2025, 12:37 UTC

Market Talk

Fund Manager Roundup: U.S. Treasurys in Focus -2-

4 juil. 2025, 12:30 UTC

Market Talk

Fund Manager Roundup: U.S. Tariff Deadline Key for Dollar Outlook, U.K. Fiscal Risks In Focus for Pound

4 juil. 2025, 12:15 UTC

Market Talk

Targeted Tariffs Would Likely Support Dollar -- Market Talk

4 juil. 2025, 12:13 UTC

Market Talk

Further Pause in Tariffs Would Have Unclear Impact on Dollar -- Market Talk

4 juil. 2025, 12:02 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

Comparaison

Variation de prix

Xencor Inc prévision

Objectif de Prix

By TipRanks

219.36% hausse

Prévisions sur 12 Mois

Moyen 26.89 USD  219.36%

Haut 38 USD

Bas 6 USD

Basé sur 11 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

11 ratings

10

Achat

0

Maintien

1

Vente

Score Technique

By Trading Central

7.87 / 10.84Support & Résistance

Court Terme

Strong Bearish Evidence

Moyen Terme

Weak Bearish Evidence

Long Terme

Bearish Evidence

Sentiment

By Acuity

115 / 375Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Xencor Inc

Xencor, Inc. is a clinical-stage biopharmaceutical company that is focused on discovering and developing engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The Company uses its engineering capabilities to enable its understanding of protein structure and interactions to design XmAb technologies and develop candidates with properties. Its antibody design is focused on the segment of antibodies that interact with target antigens. It is focused on the Fc domain, which is the part of an antibody that interacts with various segments of the immune system and controls antibody structure. The Fc domain is constant and interchangeable among antibodies, and its engineered Fc domains are the XmAb technology, which can be readily substituted for natural Fc domains. Its drug candidates include Plamotamab, XmAb717, Vibecotamab, Tidutamab, XmAb841, XmAb104, XmAb306, XmAb104, XmAb564 and XmAb698.